Spanish CDMO working ahead of EU serialisation deadline

6 Dec 2018

Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.

CDMO Idifarma has confirmed it is ready to meet forthcoming EU serialisation regulations.

Spanish CDMO working ahead of EU serialisation deadline

Following a €200k investment, the Antares Vision Print&Check EVO-TE carton serialisation station is now installed and fully operational at Idifarma’s EU-GMP approved plant in Pamplona, Spain.

The announcement comes ahead of the EU Falsified Medicines Directive’s (EU FMD) February 2019 deadline for the serialisation of licensed drug products.

Luis Oquiñena, general manager and co-founder of Idifarma said: “Supporting our customers to meet new regulatory requirements and combat counterfeit medicines is very important to us.

“We have worked closely with our customers, the manufacturers of this machine and track and trace software vendors like TraceLink to ensure that our capabilities meet both existing and potential new clients’ needs.

“This machine offers us the flexibility to upgrade for future regulatory or client requirements and will enable us to help protect our clients’ products and the public against counterfeit pharmaceuticals.”

The industry-wide EU FMD regulation is a legal requirement for all pharmaceutical companies intended to improve traceability of drugs, help in the fight against counterfeit products entering the supply chain and ultimately improve patient safety.

Oquiñena added: “Our investment offers real support to our clients as they too prepare to meet the regulations. Not only can we serialise commercial batches manufactured by Idifarma for clients, but we can also offer standalone serialisation services as an outsourcing partner.

“As the deadline draws closer, we are seeing heightened interest for these specialised outsourced services and fully expect to see demand increase even further in early 2019.”

The investment in serialisation follows the expansion of both its spray drying and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds, and niche pharmaceuticals requiring small batches.

Read More

Related news

Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more